Brief: Amplia Enters Into Second Agreement With Korean Drug Screening Company Next&Bio
Dec 19 (Reuters) - Amplia Therapeutics Ltd ATX.AX: AMPLIA ENTERS INTO SECOND AGREEMENT WITH KOREAN SPECIALIST DRUG SCREENING COMPANY NEXT&BIO TO EXPLORE COMBINATION THERAPY WITH FAK INHIBITOR AND KRAS INHIBITORS Source text: ID:nGNX7m59dk Further company coverage: ATX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement